Agilent Technologies (NYSE:A) Price Target Raised to $150.00

Agilent Technologies (NYSE:A) had its target price raised by Barclays from $125.00 to $150.00 in a research report report published on Thursday morning,Benzinga reports. Barclays currently has an equal weight rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. Robert W. Baird raised their target price on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Wall Street Zen cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Finally, Evercore ISI decreased their price objective on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a report on Thursday, August 28th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $142.17.

Agilent Technologies Trading Up 2.3%

Shares of A opened at $141.91 on Thursday. The stock has a market capitalization of $40.23 billion, a P/E ratio of 33.31, a PEG ratio of 4.62 and a beta of 1.26. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The firm has a fifty day simple moving average of $122.80 and a two-hundred day simple moving average of $116.37.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.7%. Agilent Technologies’s payout ratio is 23.24%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Verdence Capital Advisors LLC grew its stake in shares of Agilent Technologies by 5.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 86 shares during the period. M&T Bank Corp lifted its holdings in Agilent Technologies by 0.4% during the second quarter. M&T Bank Corp now owns 23,205 shares of the medical research company’s stock valued at $2,738,000 after purchasing an additional 86 shares in the last quarter. CENTRAL TRUST Co boosted its position in shares of Agilent Technologies by 3.7% in the second quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company’s stock worth $298,000 after purchasing an additional 89 shares during the period. Burney Co. boosted its position in shares of Agilent Technologies by 4.8% in the second quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock worth $231,000 after purchasing an additional 90 shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in shares of Agilent Technologies by 3.0% in the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock worth $403,000 after purchasing an additional 102 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.